Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3602 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Inhibitex and FermaVir shareholders approve merger

The transaction adds FV-100, an orally bioavailable bicyclic nucleoside analogue for the treatment of shingles and a series of preclinical compounds for the treatment of human cytomegalovirus disease

Progenics prices public offering shares

UBS Investment Bank, CIBC World Markets and Morgan Stanley acted as joint book-running managers for the offering. The price to the public is $23.15, and proceeds to the

Roche extends offer for Ventana

Roche’s $3 billion hostile bid for Ventana is set to expire on November 1. Roche has said approximately 63,541 shares have been tendered pursuant to the offer. That’s

Preos granted US orphan drug status

Dr Francois Nader, executive vice president and COO, said: “We greatly appreciate the FDA’s support of our efforts to evaluate the use of Preos as a hormone replacement